Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex Pharmaceuticals (NASDAQ:VRTX) presented positive long-term data for its gene therapy Casgevy and issued a business update on the product. The data showed 93% of treated patients ...

Vertex Pharmaceuticals and Crispr Therapeutics, which developed Casgevy, have not publicly said how many patients have received the therapy so far. WIRED reached out to all 34 US hospitals ...

Vertex Pharmaceuticals' suzetrigine is an investigational pain treatment. It will seek label expansions thereafter, including ...